UPCC 09118:A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  breast cancer
• Age: - 99 Years
• Gender: All